FOXO1 impairs whereas statin protects endothelial function in diabetes through reciprocal regulation of Krüppel-like factor 2

Hae Young Lee, Seock Won Youn, Hyun Jai Cho, Yoo Wook Kwon, Sae Won Lee, Sung Jin Kim, Young Bae Park, Byung Hee Oh, Hyo Soo Kim

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Aims Krüppel-like factor 2 (KLF2) is implicated as a key molecule maintaining endothelial function. This study was designed to evaluate the reciprocal regulation of KLF2 by the forkhead transcription factor FOXO1, and the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin, in hyperglycaemic conditions.Methods and resultsExposure of human umbilical vein endothelial cells to 30 mM glucose activated FOXO1 and suppressed KLF2. These effects were reversed by FOXO1 small interfering RNA. Adenoviral transfection of constitutively active FOXO1 suppressed KLF2 expression. Interestingly, atorvastatin inhibited FOXO1 by increasing phosphorylation and also by inhibiting nuclear localization and replenished KLF2 in high-glucose conditions. This effect of atorvastatin was attenuated by mevalonate. Chromatin immunoprecipitation analysis demonstrated that glucose increased whereas atorvastatin decreased FOXO1 binding to the promoter region of the KLF2 gene. In the vessels of Otsuka Long-Evans Tokushima Fatty rats, animal models of type 2 diabetes, FOXO1 was activated and KLF2 was suppressed, and this was reversed by atorvastatin treatment. The arteries from Otsuka Long-Evans Tokushima Fatty rats showed impairment of endothelium-dependent vasodilatation, and both atorvastatin and KLF2 gene therapies restored it.ConclusionsSuppression of KLF2 by FOXO1 may be a plausible mechanism of diabetic endothelial dysfunction. High-glucose-induced, FOXO1-mediated KLF2 suppression was reversed by atorvastatin, suggesting that intensive statin treatment could be a therapeutic option in diabetic vascular dysfunction.

Original languageEnglish (US)
Pages (from-to)143-152
Number of pages10
JournalCardiovascular Research
Volume97
Issue number1
DOIs
StatePublished - Jan 1 2013

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Inbred OLETF Rats
Glucose
Transcription Factor 3
Forkhead Transcription Factors
Mevalonic Acid
Chromatin Immunoprecipitation
Human Umbilical Vein Endothelial Cells
Atorvastatin Calcium
Genetic Promoter Regions
Vasodilation
Genetic Therapy
Type 2 Diabetes Mellitus
Small Interfering RNA
Endothelium
Transfection
Blood Vessels
Oxidoreductases
Therapeutics
Animal Models

Keywords

  • Diabetes
  • FOXO1
  • Krüppel-like factor 2
  • Statin

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

FOXO1 impairs whereas statin protects endothelial function in diabetes through reciprocal regulation of Krüppel-like factor 2. / Lee, Hae Young; Youn, Seock Won; Cho, Hyun Jai; Kwon, Yoo Wook; Lee, Sae Won; Kim, Sung Jin; Park, Young Bae; Oh, Byung Hee; Kim, Hyo Soo.

In: Cardiovascular Research, Vol. 97, No. 1, 01.01.2013, p. 143-152.

Research output: Contribution to journalArticle

Lee, HY, Youn, SW, Cho, HJ, Kwon, YW, Lee, SW, Kim, SJ, Park, YB, Oh, BH & Kim, HS 2013, 'FOXO1 impairs whereas statin protects endothelial function in diabetes through reciprocal regulation of Krüppel-like factor 2', Cardiovascular Research, vol. 97, no. 1, pp. 143-152. https://doi.org/10.1093/cvr/cvs283
Lee, Hae Young ; Youn, Seock Won ; Cho, Hyun Jai ; Kwon, Yoo Wook ; Lee, Sae Won ; Kim, Sung Jin ; Park, Young Bae ; Oh, Byung Hee ; Kim, Hyo Soo. / FOXO1 impairs whereas statin protects endothelial function in diabetes through reciprocal regulation of Krüppel-like factor 2. In: Cardiovascular Research. 2013 ; Vol. 97, No. 1. pp. 143-152.
@article{fea231400fb94279ab7cd7a715978262,
title = "FOXO1 impairs whereas statin protects endothelial function in diabetes through reciprocal regulation of Kr{\"u}ppel-like factor 2",
abstract = "Aims Kr{\"u}ppel-like factor 2 (KLF2) is implicated as a key molecule maintaining endothelial function. This study was designed to evaluate the reciprocal regulation of KLF2 by the forkhead transcription factor FOXO1, and the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin, in hyperglycaemic conditions.Methods and resultsExposure of human umbilical vein endothelial cells to 30 mM glucose activated FOXO1 and suppressed KLF2. These effects were reversed by FOXO1 small interfering RNA. Adenoviral transfection of constitutively active FOXO1 suppressed KLF2 expression. Interestingly, atorvastatin inhibited FOXO1 by increasing phosphorylation and also by inhibiting nuclear localization and replenished KLF2 in high-glucose conditions. This effect of atorvastatin was attenuated by mevalonate. Chromatin immunoprecipitation analysis demonstrated that glucose increased whereas atorvastatin decreased FOXO1 binding to the promoter region of the KLF2 gene. In the vessels of Otsuka Long-Evans Tokushima Fatty rats, animal models of type 2 diabetes, FOXO1 was activated and KLF2 was suppressed, and this was reversed by atorvastatin treatment. The arteries from Otsuka Long-Evans Tokushima Fatty rats showed impairment of endothelium-dependent vasodilatation, and both atorvastatin and KLF2 gene therapies restored it.ConclusionsSuppression of KLF2 by FOXO1 may be a plausible mechanism of diabetic endothelial dysfunction. High-glucose-induced, FOXO1-mediated KLF2 suppression was reversed by atorvastatin, suggesting that intensive statin treatment could be a therapeutic option in diabetic vascular dysfunction.",
keywords = "Diabetes, FOXO1, Kr{\"u}ppel-like factor 2, Statin",
author = "Lee, {Hae Young} and Youn, {Seock Won} and Cho, {Hyun Jai} and Kwon, {Yoo Wook} and Lee, {Sae Won} and Kim, {Sung Jin} and Park, {Young Bae} and Oh, {Byung Hee} and Kim, {Hyo Soo}",
year = "2013",
month = "1",
day = "1",
doi = "10.1093/cvr/cvs283",
language = "English (US)",
volume = "97",
pages = "143--152",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - FOXO1 impairs whereas statin protects endothelial function in diabetes through reciprocal regulation of Krüppel-like factor 2

AU - Lee, Hae Young

AU - Youn, Seock Won

AU - Cho, Hyun Jai

AU - Kwon, Yoo Wook

AU - Lee, Sae Won

AU - Kim, Sung Jin

AU - Park, Young Bae

AU - Oh, Byung Hee

AU - Kim, Hyo Soo

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Aims Krüppel-like factor 2 (KLF2) is implicated as a key molecule maintaining endothelial function. This study was designed to evaluate the reciprocal regulation of KLF2 by the forkhead transcription factor FOXO1, and the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin, in hyperglycaemic conditions.Methods and resultsExposure of human umbilical vein endothelial cells to 30 mM glucose activated FOXO1 and suppressed KLF2. These effects were reversed by FOXO1 small interfering RNA. Adenoviral transfection of constitutively active FOXO1 suppressed KLF2 expression. Interestingly, atorvastatin inhibited FOXO1 by increasing phosphorylation and also by inhibiting nuclear localization and replenished KLF2 in high-glucose conditions. This effect of atorvastatin was attenuated by mevalonate. Chromatin immunoprecipitation analysis demonstrated that glucose increased whereas atorvastatin decreased FOXO1 binding to the promoter region of the KLF2 gene. In the vessels of Otsuka Long-Evans Tokushima Fatty rats, animal models of type 2 diabetes, FOXO1 was activated and KLF2 was suppressed, and this was reversed by atorvastatin treatment. The arteries from Otsuka Long-Evans Tokushima Fatty rats showed impairment of endothelium-dependent vasodilatation, and both atorvastatin and KLF2 gene therapies restored it.ConclusionsSuppression of KLF2 by FOXO1 may be a plausible mechanism of diabetic endothelial dysfunction. High-glucose-induced, FOXO1-mediated KLF2 suppression was reversed by atorvastatin, suggesting that intensive statin treatment could be a therapeutic option in diabetic vascular dysfunction.

AB - Aims Krüppel-like factor 2 (KLF2) is implicated as a key molecule maintaining endothelial function. This study was designed to evaluate the reciprocal regulation of KLF2 by the forkhead transcription factor FOXO1, and the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin, in hyperglycaemic conditions.Methods and resultsExposure of human umbilical vein endothelial cells to 30 mM glucose activated FOXO1 and suppressed KLF2. These effects were reversed by FOXO1 small interfering RNA. Adenoviral transfection of constitutively active FOXO1 suppressed KLF2 expression. Interestingly, atorvastatin inhibited FOXO1 by increasing phosphorylation and also by inhibiting nuclear localization and replenished KLF2 in high-glucose conditions. This effect of atorvastatin was attenuated by mevalonate. Chromatin immunoprecipitation analysis demonstrated that glucose increased whereas atorvastatin decreased FOXO1 binding to the promoter region of the KLF2 gene. In the vessels of Otsuka Long-Evans Tokushima Fatty rats, animal models of type 2 diabetes, FOXO1 was activated and KLF2 was suppressed, and this was reversed by atorvastatin treatment. The arteries from Otsuka Long-Evans Tokushima Fatty rats showed impairment of endothelium-dependent vasodilatation, and both atorvastatin and KLF2 gene therapies restored it.ConclusionsSuppression of KLF2 by FOXO1 may be a plausible mechanism of diabetic endothelial dysfunction. High-glucose-induced, FOXO1-mediated KLF2 suppression was reversed by atorvastatin, suggesting that intensive statin treatment could be a therapeutic option in diabetic vascular dysfunction.

KW - Diabetes

KW - FOXO1

KW - Krüppel-like factor 2

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=84871797076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871797076&partnerID=8YFLogxK

U2 - 10.1093/cvr/cvs283

DO - 10.1093/cvr/cvs283

M3 - Article

C2 - 23002242

AN - SCOPUS:84871797076

VL - 97

SP - 143

EP - 152

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 1

ER -